The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection
Autor
Beddingfield, Brandon J.
Iwanaga, Naoki
Chapagain, Prem P.
Zheng, Wenshu
Roy, Chad J.
Hu, Tony Y.
Kolls, Jay K.
Bix, Gregory J.
Institución
Resumen
Many efforts to design and screen therapeutics for the current severe acute respiratory
syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry
by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the
potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism,
and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2), and the
interaction between α5β1 integrin and ACE2 using a novel molecule ATN-161 represents a
promising approach to treat COVID-19.